Selective loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality by Gogola, E, Duarte, AA, de Ruiter, JR, Wiegant, WW, Schmid, JA, de Bruijn, R, James, DI, Llobet, SG, Vis, DJ, Annunziato, S, van den Broek, B, Barazas, M, Kersbergen, A, van de Ven, M, Tarsounas, M, Ogilvie, DJ, van Vugt, M, Wessels, LFA, Bartkova, J, Gromova, I, Andújar-Sánchez, M, Bartek, J, Lopes, M, van Attikum, H, Borst, P, Jonkers, J, Rottenberg, S

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers by Zingg, D, Bhin, J, Yemelyanenko, J, Kas, SM, Rolfs, F, Lutz, C, Lee, JK, Klarenbeek, S, Silverman, IM, Annunziato, S, Chan, CS, Piersma, SR, Eijkman, T, Badoux, M, Gogola, E, Siteur, B, Sprengers, J, de Klein, B, de Goeij-de Haas, RR, Riedlinger, GM, Ke, H, Madison, R, Drenth, AP, van der Burg, E, Schut, E, Henneman, L, van Miltenburg, MH, Proost, N, Zhen, H, Wientjens, E, de Bruijn, R, de Ruiter, JR, Boon, U, de Korte-Grimmerink, R, van Gerwen, B, Féliz, L, Abou-Alfa, GK, Ross, JS, van de Ven, M, Rottenberg, S, Cuppen, E, Chessex, AV, Ali, SM, Burn, TC, Jimenez, CR, Ganesan, S, Wessels, LFA, Jonkers, J